Takeda's Ninlaro falls short in first line multiple myeloma

Takeda’s Ninlaro (ixazomib) has fallen short in a late-stage study testing it in combination with Bristol-Myers Squibb/Celgene’s Revlimid and chemo in newly diagnosed multiple myeloma.

BMS/AbbVie's combo falls short in untreated multiple myeloma...

Adding Bristol-Myers Squibb/AbbVie's Empliciti to Revlimid, developed by BMS' recently acquired Celgene unit, does not improve survival in untreated multiple myeloma, a study has shown.

BMS joins with Voluntis to create cancer support app

Bristol-Myers Squibb has joined with digital therapeutics firm Voluntis to create an app that will support cancer patients.

NICE backs Celgene’s Revlimid for chemo-free lymphoma therap...

Gilead poaches oncology expert Quigley from BMS

Gilead has poached an oncology research leader from Bristol-Myers Squibb, appointing Michael Quigley as senior vice president of research biology.

BMS builds case for long-term use of Opdivo in kidney cancer

Bristol-Myers Squibb has unveiled long-term results from its immunotherapy Opdivo in the most common form of kidney cancer, showing that more than a quarter of patients were alive after fiv